NEW YORK (GenomeWeb News) – Roche has received the CE-IVD Mark for its new dual-target HIV-1 test allowing it to be used for clinical use throughout the European Union, the firm said today.
 
The firm’s Cobas AmpliPrep/Cobas TaqMan HIV-1 Test, v2.0 simultaneously amplifies and detects two separate regions of the HIV-1genome, which Roche said enables reliable results even when mutations are present. The test also uses real-time PCR to quantify the amount of HIV-1RNA in a patient’s blood.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.